Clinical trials: Probable Alzheimer's Disease
Alzheimer's Disease
The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease
This is a national multicenter, double-blind, randomized, parallel-group trial of 12 months in duration. Following a 4 week wash-out period, subjects will be randomized to one of 2 treatment groups: (1) galantamine CR 24 mg/day…
- Trial name
- AD-Combi (NCT01921972)
- Testing
- Galantamine CR, Memantine
- Volunteers
- 232 people
- Sponsor
- Charite University, Berlin, Germany
Alzheimer Disease, Dementia
Detecting Probable Alzheimer's Disease From Speech Using Linguistical Analysis
The object of this study is to investigate the use of linguistic deficits from speech samples for the early detection of Mild Cognitive Impairment and probable Alzheimer's disease.
- Trial name
- NCT04041895
- Testing
- Audio speech recording
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- East Tennessee State University
Alzheimer's Disease
A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)
This study is designed to confirm the efficacy, the tolerability, the patient compliance and the caregiver satisfaction with rivastigmine target patch size 10 cm^2 in patients with probable Alzheimer's Disease (Mini-Mental State…
- Trial name
- EXTRA (NCT00622713)
- Testing
- Rivastigmine transdermal patch
- Where
- France
- Volunteers
- 228 people
- Sponsor
- Novartis
Alzheimer's Disease With Vascular Pathology
A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology
This study is being conducted to test the safety, tolerability, and pharmacokinetics of the investigational drug CY6463 compared with placebo in individuals who are aged 60 years or older and have Alzheimer's disease (AD) along…
- Trial name
- NCT04798989
- Testing
- CY6463
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Tisento Therapeutics
Alzheimer's Disease, Dementia
Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease
This study will evaluate the pharmacological efficacy on language capability and compliance with combination of new Ebixa oral pump and donepezil compared to donepezil only in patients with probable Alzheimer's disease.
- Trial name
- ROMEO-AD (NCT01849042)
- Testing
- Ebixa, donepezil
- Where
- South Korea
- Volunteers
- 188 people
- Sponsor
- Konkuk University Medical Center
Alzheimer Disease
A Study of Seltorexant in Participants With Probable Alzheimer's Disease
The purpose of this study is to investigate the effect of seltorexant versus placebo on the sum of Agitation and Aggression domain scores (A plus A) of the Neuropsychiatric Inventory-Clinician rating (NPI-C) in participants with…
- Trial name
- NCT05307692
- Testing
- Seltorexant
- Where
- 25 sites in United States
- Volunteers
- 88 people
- Sponsor
- Janssen Research & Development, LLC
Alzheimer Type Dementia
An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia
The purpose of this study is to evaluate the efficacy and safety of two fixed dose (1200mg/day, 1600mg/day) of INM-176 (a drug of treating dementia) comparing with donepezil for treatment for patients with Alzheimer type dementia.
- Trial name
- NCT01245530
- Testing
- Aricept, INM-176
- Where
- South Korea
- Volunteers
- 280 people
- Sponsor
- Whanin Pharmaceutical Company
Alzheimer Disease
A Phase 3 Study of NE3107 in Probable Alzheimer's Disease
U.S. multicenter, parallel group study designed to evaluate the safety and efficacy of oral 20 mg twice daily (BID) NE3107 vs placebo in 400 adult subjects with mild to moderate probable AD.
- Trial name
- NCT04669028
- Testing
- NE3107
- Where
- United States
- Volunteers
- 439 people
- Sponsor
- BioVie Inc.
Alzheimer Disease, Amyloid Beta-Protein
Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers
The aim of this study is to evaluate the efficacy, safety of a single dose of BAY 94-9172 (ZK 6013443) as an investigational medicinal product (IMP) in detecting cerebral protein-plaque (amyloid beta) with positron emission…
- Trial name
- NCT00750282
- Testing
- Florbetaben (BAY94-9172)
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 422 people
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer's Disease Dementia
Study on Clinical Characteristics of Patients With Probable Alzheimer's Dementia Stratified by Blood Biomarkers
This is a prospective, observational cohort study. The primary objective is to characterize the clinical features and mechanisms of behavioral and psychological symptoms of dementia (BPSD) in patients with probable Alzheimer's…
- Trial name
- AD-BBM (NCT07875998)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tianjin Anding Hospital
Mild to Moderate Alzheimer's Disease
Study of LM11A-31-BHS in Mild-moderate AD Patients
The purpose of this study is to determine the safety of 2 doses of LM11A-31-BHS in 180 patients with Alzheimer's Disease versus placebo and to access biomarker and clinical exploratory endpoints of LM11A-31-BHS
- Trial name
- NCT03069014
- Testing
- 400mg LM11A-31-BHS, 800mg LM11A-31-BHS
- Where
- 21 sites in Austria, Czechia and 3 more
- Volunteers
- 242 people
- Sponsor
- PharmatrophiX Inc.
Alzheimer Disease, Healthy Volunteers
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
The overall goal of this imaging trial is to evaluate [18F]MNI-958, a tau targeted PET radioligand, in individuals with Alzheimer's disease (AD), Progressive Supranuclear Palsy (PSP), and healthy volunteers (HV).
- Conditions
- Alzheimer Disease, Healthy Volunteers, Progressive Supranuclear Palsy
- Trial name
- NCT03058965
- Testing
- [18F]MNI-958, [18F]Florbetapir, DaTscan
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Mild Cognitive Impairment, Alzheimer's Disease
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically…
- Trial name
- NCT01028053
- Testing
- Flutemetamol (18F) Injection
- Where
- United States
- Volunteers
- 365 people
- Sponsor
- GE Healthcare
Alzheimer Disease
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
This is a phase 2, open-label, multiple-center, non-randomized single dose study to assess the safety and efficacy of [18F]NAV4694 PET imaging in detecting beta-amyloid plaque in the brain in subjects with probable AD compared…
- Trial name
- NCT01680588
- Testing
- [18F]NAV4694
- Where
- 7 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Navidea Biopharmaceuticals
Alzheimer Disease, Memory Disorders
Exercise Treatment of Mild-Stage Probable Alzheimer's Disease
The purpose of the study is to determine if participation in an exercise program helps memory loss from getting worse, and if it improves daily functioning and attitudes of those with probable Alzheimer's disease.
- Conditions
- Alzheimer Disease, Memory Disorders, Dementia
- Trial name
- NCT00403507
- Testing
- Participation in a monitored exercise program, Personalized aerobic and strength training.
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Intermountain Health Care, Inc.
Alzheimer Disease
ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease
The primary objective of this feasibility study is to evaluate the safety of DBS-f in patients with mild Alzheimer's disease by assessing all device and/or therapy related adverse events.
- Trial name
- ADvance (NCT01608061)
- Testing
- DBS-f on, DBS-f off
- Where
- 7 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Functional Neuromodulation Ltd
Alzheimer's Disease
Safety and Efficacy of MT-4666
The objective of this study is to evaluate the safety and efficacy as assessed by the Alzheimers Disease Assessment Scale-cognitive subscale 13-item (ADAS-cog-13) of two doses of MT-4666 or placebo administered daily for 24 weeks…
- Trial name
- NCT01764243
- Testing
- MT-4666
- Where
- Japan
- Volunteers
- 450 people
- Sponsor
- Tanabe Pharma Corporation
Alzheimer Disease
Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease
The purpose of the study is to evaluate the safety and tolerability of multiple doses of NPT088 in patients with mild to moderate probable Alzheimer's Disease.
- Trial name
- NCT03008161
- Testing
- NPT088
- Where
- 23 sites in United States
- Volunteers
- 83 people
- Sponsor
- Proclara Biosciences, Inc.
Alzheimer Disease, Vascular Dementia
A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia
The purpose of this study is to evaluate the safety and efficacy of galantamine (a drug for treating dementia) compared to placebo in the treatment of patients with dementia related to cerebrovascular disease (vascular dementia)…
- Trial name
- NCT00261573
- Testing
- galantamine hydrobromide
- Volunteers
- 593 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer's Disease
A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension
This is Phase 3 study, multi-centre, double-blind, placebo controlled, parallel group to evaluate the effects of AC-SD-03 on the efficacy and safety among participants with mild to moderate Alzheimer's Disease.
- Trial name
- NCT04187547
- Testing
- Tricaprilin
- Sponsor
- Cerecin